BiotechTube

CC-42344 + Placebo

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Influenza A

Conditions

Influenza A

Trial Timeline

Feb 11, 2022 → Mar 29, 2023

NCT ID
NCT05202379

About CC-42344 + Placebo

CC-42344 + Placebo is a phase 1 stage product being developed by Cocrystal Pharma for Influenza A. The current trial status is completed. This product is registered under clinical trial identifier NCT05202379. Target conditions include Influenza A.

What happened to similar drugs?

20 of 20 similar drugs in Influenza A were approved

Approved (20) Terminated (1) Active (0)
✅Monovalent Influenza VaccineAstraZenecaApproved
✅Monovalent Influenza VaccineAstraZenecaApproved
✅Trivalent Influenza VaccineAstraZenecaApproved
✅Trivalent Influenza VaccineAstraZenecaApproved
✅FluMist trivalent (2015-2016) + FluMist Quadrivalent (2015-2016) + FluMist Quadrivalent (2017-2018)AstraZenecaApproved
✅Trivalent Influenza Virus VaccineAstraZenecaApproved
✅Vaxelis + PedvaxHIBMerckApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05202379Phase 1Completed

Competing Products

20 competing products in Influenza A

See all competitors
ProductCompanyStageHype Score
mRNA-1010ModernaPhase 1
0
mRNA-1273ModernaPhase 1
0
mRNA-1010ModernaPhase 2
0
mRNA-1083 Composition 1 Dose A Lot AModernaPhase 2
0
mRNA-1010ModernaPhase 3
0
mRNA-1011.1ModernaPhase 2
0
mRNA-1083.1ModernaPhase 2
0
mRNA-1010ModernaPhase 3
0
mRNA-1083ModernaPhase 3
0
mRNA-1073ModernaPhase 2
0
VAL-506440ModernaPhase 1
0
mRNA-1083ModernaPhase 3
0
mRNA-1083ModernaPhase 2
0
mRNA-1010ModernaPhase 3
0
VAL-339851ModernaPhase 1
0
mRNA-1018-H5ModernaPhase 3
0
mRNA-1653ModernaPhase 1
0
mRNA-1030ModernaPhase 2
0
mRNA-1018 for H5N8ModernaPhase 2
0
mRNA-1653ModernaPhase 1
0